Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Department of Anesthesiology and Intensive Care, Hôpital Nord, Marseille, 13015, France.
Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Department of Anesthesiology and Intensive Care, Hôpital Nord, Marseille, 13015, France.
Int J Antimicrob Agents. 2020 Nov;56(5):106136. doi: 10.1016/j.ijantimicag.2020.106136. Epub 2020 Aug 8.
During the Covid-19 pandemic, many intensive care unit (ICU) patients received hydroxychloroquine. The primary objective of this study was to assess the effects of hydroxychloroquine according to its plasma concentration in ICU patients. A single-center retrospective study was performed from March to April 2020 in an ICU of a university hospital. All patients admitted to the ICU with confirmed Covid-19 pneumonia and treated with hydroxychloroquine were included. The study compared 17 patients in whom the hydroxychloroquine plasma concentration was in the therapeutic target (on-target) and 12 patients in whom the plasma concentration was below the target (off-target). The follow-up of patients was 15 days. No association was found between hydroxychloroquine plasma concentration and viral load evolution (P = 0.77). There was no significant difference between the two groups for duration of mechanical ventilation, length of ICU stay, in-hospital mortality, and 15-days mortality. These findings indicate that hydroxychloroquine administration for Covid-19 patients hospitalized in ICU is not associated with improved outcomes. Larger multicenter studies are needed to confirm these results.
在 COVID-19 大流行期间，许多重症监护病房（ICU）的患者接受了羟氯喹治疗。本研究的主要目的是根据 ICU 患者的羟氯喹血浆浓度评估其疗效。这是一项 2020 年 3 月至 4 月在一所大学附属医院 ICU 进行的单中心回顾性研究。所有确诊 COVID-19 肺炎并接受羟氯喹治疗的 ICU 入院患者均被纳入研究。研究比较了羟氯喹血浆浓度在治疗目标范围内（靶标）的 17 例患者和浓度低于目标范围的 12 例患者。患者的随访时间为 15 天。羟氯喹血浆浓度与病毒载量变化之间无相关性（P=0.77）。两组间机械通气时间、ICU 住院时间、院内死亡率和 15 天死亡率无显著差异。这些发现表明，在 ICU 住院的 COVID-19 患者中使用羟氯喹治疗与改善结局无关。需要更大规模的多中心研究来证实这些结果。
